ArticleObstetric medicine2011
A novel approach to hyperemesis gravidarum: evaluation by a visual analogue scale score and treatment with transdermal clonidine.
Article in Obstetric medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA preliminary report on the symptomatic effect of clonidine in severe hyperemesis gravidarum (HG).
designObservational. SETTTING: Hospital based: Ospedale Sant'Anna, Torino, Italy. POPULATION: Twelve pregnant women, 8-16 weeks, affected by severe, refractory HG.
methodsAssessment by two clinical score indexes: Pregnancy Unique Quantification of Emesis (PUQE) score and a Visual Analogue Scale (VAS) 5-item questionnaire, filled out daily, to detect subjective improvement or worsening of symptoms.
main outcome measuresPUQE score and VAS score before and after transdermal clonidine treatment.
resultsWe found substantial improvement of symptoms and severity score indexes after four and 14 days. The comparison of pretreatment and post-treatment scores shows a significant statistical difference P < 0.0001.
conclusionTransdermal clonidine may be considered as a treatment for resistant severe HG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.